

1. Product and Company Identification

www.rxmarine.com

Product Name RXSOL-60-6605-474
Product Type SODIUM BISMUTHATE
Revised date

Company Details:

RX MARINE INTERNATIONAL
105, A wing , BSEL , TECH PARK.
VASHI ,NEW BOMBAY 400703 INDIA

Stock Point : Mumbai, Kandla, Chennai, Visakhapatnam, Kolkata, Fujairah, Muscat Barka

Phone +91 22 27815541 / 42
Fax +91 22 2781 1318 :::AOH :0091 9821214367
Email mail@rxmarine.com

2. Composition / Information on ingredients

www.rxmarine.com

2.1 Substances : SODIUM BISMUTHATE

CAS-No. : 12232-99-4

Substance name Contents CAS No

Bismuth sodium trioxide 100 % 12232-99-4

Substance.

Contains no other components or impurities which will influence the classification of the product.

3. Hazards Identification

www.rxmarine.com

3.1 Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008

Acute toxicity, Oral (Category 4), H302

For the full text of the H-Statements mentioned in this Section, see Section 16.

3.2 Label elements

Labelling according Regulation (EC) No 1272/2008

Pictogram

Signal word : Warning Hazard statement(s) H302

Harmful if swallowed.

Precautionary statement(s) none

Supplemental Hazard

Statement : none

3.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

4. First Aid Measures

www.rxmarine.com

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration.

Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water.

Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5. Fire-fighting Measures

www.rxmarine.com

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

Carbon oxides, Sodium oxides

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

6. Accidental Release Measures

www.rxmarine.com

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Avoid breathing dust.

For personal protection see section 8.

6.2 Environmental precautions Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

7. Handling and Storage

www.rxmarine.com

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Hygroscopic. Storage class (TRGS 510): Non Combustible Solids

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. Exposure controls and personal protection

www.rxmarine.com

8.1 Control parameters

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

☒ Personal protective equipment

☒ Eye/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

☒ Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industria situation of anticipated use by our customers. It should not be construed as offering an approval for any specific use scenario.

☒ Body Protection

Impervious clothing, The type of protective equipment must be selected according to the

concentration and amount of the dangerous substance at the specific workplace.

☒ Respiratory protection

For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle r (US) or type ABEKP2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Do not let product enter drains.

9. Physical and chemical properties

www.rxmarine.com

9.1 Information on basic physical and chemical properties

Odour : No data available

Odour Threshold: No data available

pH: No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range :No data available

Flash point: Not applicable

Evaporation rate: No data available

Flammability (solid, gas): No data available

Upper/lower flammability or explosive limits :No data available

Vapour pressure : No data available

Vapour density : No data available

Relative density No data available

Water solubility: No data available

Partition coefficient: noctanol/ water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity: No data available

Explosive properties : No data available

Oxidizing properties ; No data available

9.2 Other safety information

10. Stability and reactivity

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

Avoid moisture.

10.5 Incompatible materials

acids

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Sodium oxides,

Bismuth oxides Other decomposition products - No data available

In the event of fire: see section 5

11. Toxicological information

11.1 Information on toxicological effects

Acute toxicity

LD50 Oral - Rat - 420 mg/kg(Bismuth sodium trioxide)

Skin corrosion/irritation

No data available(Bismuth sodium trioxide)

Serious eye damage/eye irritation

No data available(Bismuth sodium trioxide)

Respiratory or skin sensitisation

No data available(Bismuth sodium trioxide)

Germ cell mutagenicity

No data available(Bismuth sodium trioxide)

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Reproductive toxicity

No data available(Bismuth sodium trioxide)

Specific target organ toxicity - single exposure

No data available(Bismuth sodium trioxide)

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available(Bismuth sodium trioxide)

Additional Information

RTECS: VZ1750000

Symptoms of chronic bismuth toxicity in humans consists of decreased appet line on the gums, foul breathe, gingivitis, and dermatitis. Jaundice and Bismuth nephropathy with proteinuria may occur. The kidney is the site of lower. Bismuth does pass into the amniotic fluid and into the fetus., To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.(Bismuth sodium trioxide)

12. Ecological information

www.rxmarine.com

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available(Bismuth sodium trioxide)

12.5 Results of PBT and vPvB assessment

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

No data available

13. Disposal considerations

www.rxmarine.com

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chem scrubber.

Contaminated packaging

Dispose of as unused product.

14. Transport information

www.rxmarine.com

14.1 UN number

ADR/RID: - IMDG: - IATA: -

14.2 UN proper shipping name

ADR/RID: Not dangerous goods

IMDG: Not dangerous goods

IATA: Not dangerous goods

14.3 Transport hazard class(es)

ADR/RID: - IMDG: - IATA: -

14.4 Packaging group

ADR/RID: - IMDG: - IATA: -

14.5 Environmental hazards

14.6 Special precautions for user

No data available

15. Regulatory information

www.rxmarine.com

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

15.2 Chemical safety assessment

For this product a chemical safety assessment was not carried out

16. Other information

www.rxmarine.com

Abbreviations and acronyms : PBT: persistent, bioaccumulative and toxic.

vPvB: very persistent and very bioaccumulative

Sources of key data used : REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006

Further information : None.

In accordance with REACH Regulation (CE) N° 1907/2006 and with CLP Regulation (CE) N° 1272/2008

DISCLAIMER OF LIABILITY :The information in this SDS was obtained from sources which we believe are reliable. However, the information is provided without any warranty, express or implied, regarding its correctness. The conditions or methods of handling, storage, use or disposal of the product are beyond our control and may be beyond our knowledge. For this and other reasons, we do not assume responsibility and expressly disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the product. This MSDS was prepared and is to be used only for this product. If the product is used as a component in another product, this MSDS information may not be applicable.